Apellis Pharmaceuticals, Inc.·4

Feb 27, 4:32 PM ET

Lewis Karen 4

4 · Apellis Pharmaceuticals, Inc. · Filed Feb 27, 2023

Insider Transaction Report

Form 4
Period: 2023-02-23
Lewis Karen
Chief People Officer
Transactions
  • Sale

    Common Stock

    2023-02-23$68.76/sh1,104$75,91141,430 total
Footnotes (1)
  • [F1]Sale originated from established 10b5-1 trading plan.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT